Literature DB >> 17196664

Clinical efficacy and cognitive side effects of bifrontal versus right unilateral electroconvulsive therapy (ECT): a short-term randomised controlled trial in pharmaco-resistant major depression.

Gerhard W Eschweiler1, Reinhard Vonthein, Ruediger Bode, Michael Huell, Andreas Conca, Oliver Peters, Stefan Mende-Lechler, Julia Peters, Dorothee Klecha, Michael Prapotnik, Jan DiPauli, Barbara Wild, Christian Plewnia, Mathias Bartels, Wilfried Schlotter.   

Abstract

BACKGROUND: In most studies right unilateral electroconvulsive therapy (ECT) has been shown to cause fewer cognitive side effects but less antidepressant efficacy compared with bi(fronto)temporal ECT at certain intensities. AIMS: To compare the short-term efficacy and side effects of right unilateral ECT and bifrontal ECT.
METHODS: In a double-blind randomised controlled clinical trial, 92 patients diagnosed with pharmaco-resistant major depression received either six right unilateral ECT treatments (250% stimulus intensity of titrated threshold) or six bifrontal ECT (150% of threshold) treatments over a 3-week period. Concomitant psychotropic medications were continued during ECT treatments. The severity of depression and cognitive status was assessed prior to the first ECT and one day after the sixth ECT using the 21-item Hamilton Depression Rating Scale and the modified Mini Mental State Examination.
RESULTS: Eight patients did not complete the course of the study due to minor side effects or withdrawal of consent. The mean Hamilton Depression score decreased from 27 to 17 points in both groups of 46 patients, resulting in 12 responders (primary endpoint defined as a decrease >50%) in each patient group (95% confidence interval for the odds ratio from 0.35 to 2.8). There was no reduction in the modified Mini Mental State score (mean score 86 of 100 points).
CONCLUSIONS: Both bifrontal and right unilateral electrode placements in ECT were reasonably safe and moderately efficacious in reducing symptoms of pharmaco-resistant major depression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17196664     DOI: 10.1016/j.jad.2006.11.012

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  7 in total

Review 1.  Multimodal approaches to define network oscillations in depression.

Authors:  Otis Lkuwamy Smart; Vineet Ravi Tiruvadi; Helen S Mayberg
Journal:  Biol Psychiatry       Date:  2015-01-28       Impact factor: 13.382

Review 2.  Depression in adults: drug and physical treatments.

Authors:  Andrea Cipriani; Corrado Barbui; Rob Butler; Simon Hatcher; John Geddes
Journal:  BMJ Clin Evid       Date:  2011-05-25

Review 3.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

4.  Psychological benefits 2 and 4 weeks after a single treatment with near infrared light to the forehead: a pilot study of 10 patients with major depression and anxiety.

Authors:  Fredric Schiffer; Andrea L Johnston; Caitlin Ravichandran; Ann Polcari; Martin H Teicher; Robert H Webb; Michael R Hamblin
Journal:  Behav Brain Funct       Date:  2009-12-08       Impact factor: 3.759

5.  Adverse effects of electroconvulsive therapy on cognitive performance.

Authors:  Sasha S Getty; Lawrence R Faziola
Journal:  Ment Illn       Date:  2017-10-19

6.  Electroconvulsive Therapy Hasn't Negative Effects on Short-Term Memory Function, as Assessed Using a Bedside Hand-Held Device.

Authors:  Helge H O Müller; Mareen Reike; Simon Grosse-Holz; Mareike Röther; Caroline Lücke; Alexandra Philipsen; Johannes Kornhuber; Teja W Grömer
Journal:  Ment Illn       Date:  2017-06-28

Review 7.  Vagus Nerve Stimulation (VNS) and Other Augmentation Strategies for Therapy-Resistant Depression (TRD): Review of the Evidence and Clinical Advice for Use.

Authors:  Helge H O Müller; Sebastian Moeller; Caroline Lücke; Alexandra P Lam; Niclas Braun; Alexandra Philipsen
Journal:  Front Neurosci       Date:  2018-04-10       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.